Bivalent KDP Peptide to Enhance Neurite Growth for Traumatic Brain Injury

A silent epidemic of modern world and largely neglected field in drug development is traumatic brain injury. There is no treatment available for the patients suffering from brain trauma. Peptide is a naturally occurring biological alternative that could represent a new generation of future medications. Authors have designed and modified the C-terminal amino acids of KDI peptide responsible for neurite growth. The inclusion of a Cys (C), Gly (G), Cys and Pro (P) amino acids in the sequence leads to the possibility of better binding with the target receptor 3T1M as compared to the known KDI sequence for neurite growth. Studies on human SH-SY5Y cells for neurite outgrowth demonstrates that the CGCKDP could plausibly be useful in neuroregeneration in neurodegenerative disorders by neurite growth formation.